Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beclomethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | USP2 | O75604 | 6/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclomethasone Dipropionate SCHEMBL6055708 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL10493593 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL6941956 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL6890 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL6055713 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL13653326 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL9768491 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL10392062 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL19681908 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL5095 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| EP-3527198-B1 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2024-10-09 | — | — | EP | disclosed |
| EP-3569222-B1 | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2024-06-26 | — | — | EP | disclosed |
| US-20240029838-A1 | METHODS FOR TREATING AND PREVENTING SYMPTOMS OF ASTHMA WITH A CORTICOSTEROID PHARMACEUTICAL COMPOSITION | ASTRAZENECA UK LIMITED (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| US-11756656-B2 | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition | ASTRAZENECA UK LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
| US-11628175-B2 | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-04-18 | — | — | US | disclosed |
| EP-3412277-B1 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2022-12-14 | — | — | EP | disclosed |
| EP-3527199-B1 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2022-09-07 | — | — | EP | disclosed |
| EP-3527197-B1 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2022-09-07 | — | — | EP | disclosed |
| US-8679512-B2 | Topical formulation comprising a corticosteroid as active ingredient | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-03-25 | — | — | US | disclosed |
| US-20130189324-A1 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-25 | — | — | US | disclosed |
| US-8420060-B2 | Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| US-20120301511-A1 | TOPICAL FORMULATION COMPRISING A CORTICOSTEROID AS ACTIVE INGREDIENT | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-11-29 | — | — | US | disclosed |
| US-20110212137-A1 | INHALABLE PHARMACEUTICAL COMPOSITION | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20100323998-A1 | TOPICAL COMPOSITION CONTAINING THE COMBINATION OF MUPIROCIN AND BECLOMETHASONE | GLENMARK PHARMACEUTICALS LTD. (IN) | 2010-12-23 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | NR3C1 4651/4885CYP3A4 4180/4885USP2 276/4885 |
| US-20100323998-A1 | TOPICAL COMPOSITION CONTAINING THE COMBINATION OF MUPIROCIN AND BECLOMETHASONE | CUTA, TSLP, CYP51A1 | NR3C1 250/4885CYP3A4 292/4885USP2 2755/4885 |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | NR3C1 1/4885CYP3A4 728/4885USP2 1154/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | NR3C1 3/4885CYP3A4 331/4885USP2 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.